SCHEMBL7201540

SCHEMBL7201540

NC(=O)N1CCC(S(=O)(=O)c2ccc(-c3ccc(F)cc3)cc2)C(O)(C(=O)O)C1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADAMTS4 O75173 1/20 0.39
MMP1 P03956 1/20 0.39
ADAM17 P78536 1/20 0.39
ADAMTS1 Q9UHI8 1/20 0.39
ADAMTS7 Q9UKP4 1/20 0.39
ADAMTS5 Q9UNA0 1/20 0.39
RORC P51449 3/20 0.38
MMP13 P45452 2/20 0.37
HSD11B1 P28845 1/20 0.37
PTGS2 P35354 1/20 0.36
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA7 P43166 1/20 0.36
CA9 Q16790 1/20 0.36
CA14 Q9ULX7 1/20 0.36
MMP8 P22894 4/20 0.35
MMP3 P08254 3/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7201014 0.91 SMN1; SMN2 (0.41) MMP1MMP13CA12CA1CA2
SCHEMBL7199692 0.90 PARP10 (0.41) MMP1ADAM17RORCMMP13MMP8
SCHEMBL7202567 0.90 MMP13 (0.40) MMP1MMP13PTGS2CA12CA1
SCHEMBL7300738 0.89 MMP13 (0.48) MMP1MMP13KDM4E
SCHEMBL7204066 0.89 ALDH1A1 (0.38) ADAMTS4MMP1ADAMTS5MMP13CA12
SCHEMBL7205673 0.86 MMP1 (0.39) MMP1RORCMMP13L3MBTL1MAPT
SCHEMBL7205455 0.86 MMP9 (0.44) MMP1ADAMTS7ADAMTS5MMP13MMP8
SCHEMBL7205420 0.85 MMP1 (0.45) ADAMTS4MMP1ADAM17RORCMMP13
SCHEMBL7203105 0.84 MMP13 (0.38) MMP1MMP13CA12CA1CA2
SCHEMBL7290273 0.83 MGLL (0.41) MMP1RORCMMP13CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6608104-B2 Antiarthritic agents; anticancer agents PFIZER INC 2003-08-19 US disclosed
US-20020019534-A1 Gem substituted hydroxamic acids PFIZER INC. 2002-02-14 US disclosed
EP-1138680-A1 Gem substituted sulfonyl hydroxamic acids as MMP inhibitors Pfizer Products Inc. (US) 2001-10-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019534-A1 Gem substituted hydroxamic acids MMP14, TOP2A, ADAMTS1 ADAMTS4 26/4885MMP1 8/4885ADAM17 162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.